预约演示
更新于：2025-11-28
Vonoprazan Fumarate
富马酸伏诺拉生
更新于：2025-11-28
概要
基本信息
药物类型 小分子化药 |
别名 VONOPION、Vonoprazan、Vonoprazan fumarate (JAN/USAN) + [14] |
作用方式 阻滞剂 |
作用机制 H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H20FN3O6S |
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N |
CAS号881681-01-2 |
关联
472
项与 富马酸伏诺拉生 相关的临床试验ChiCTR2500113032
Comparative Effectiveness of Vonoprazan Dosing Strategies in Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication
NCT06851559
A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks
ChiCTR2500112845
Effect of Vonoprazan-Amoxicillin Combined with Compound Lactobacillus acidophilus on Symptoms and Gut Microbiome in Patients with Functional Constipation
100 项与 富马酸伏诺拉生 相关的临床结果
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的转化医学
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的专利（医药）
登录后查看更多信息
792
项与 富马酸伏诺拉生 相关的文献（医药）2026-02-01JOURNAL OF ETHNOPHARMACOLOGY
In vivo and in silico assays demonstrate that the hydroalcoholic extract of Aloysia polystachya and carvone promote anti-ulcer effects
Article
作者: Maccagnan, Juliana C ; Freschi, Khetlyn ; Steffler, Amanda M ; Borba, Ana L T ; Gutiérrez, Max Vidal ; Somensi, Lincon B ; da Silva, Luisa Mota ; Dalla Cort, Tainara V T ; Miorando, Daniela ; Ferraz, Cleidiane V ; Von Dentz, André L ; Marcelino, Adan P N ; Roman, Maria I ; Oss, Camile F ; Dalla Vecchia, Cristian A ; Roman Junior, Walter Antônio
ETHNOPHARMACOLOGICAL IMPORTANCE:
Aloysia polystachya (Griseb.) Moldenke is a medicinal plant that has long been used in South American medicine to treat a variety of diseases, most notably gastrointestinal issues. Despite its well-known ethnobotanical usage, this plant's putative anti-gastric ulcer action has yet to be investigated.
AIM OF THE STUDY:
To evaluate the gastroprotective and gastric healing effects of the hydroalcoholic extract from Aloysia polystachya (HEAp) and its bioactive compound, carvone, through both in vivo and in silico approaches. Additionally, it seeks to elucidate the pharmacological mechanisms underlying these biological effects.
MATERIALS AND METHODS:
First, phytochemical tests were performed with HEAp. Next, to demonstrate the gastroprotective activities, rats were orally treated with HEAp (30, 100, or 300 mg/kg) or carvone (3 mg/kg) before induction with ulcerative agents (ethanol or piroxicam). Furthermore, the role of prostaglandins, α-2 adrenergic receptors, nitric oxide, and sulfhydryl compounds were investigated. Additionally, the antisecretory activity of HEAp was investigated using a pylorus ligation model. For gastric healing analysis, acetic acid-induced chronic ulcer was used, in which rats were treated with HEAp at 100 mg/kg. Biochemical evaluations included measurements of myeloperoxidase (MPO), superoxide dismutase (SOD), glutathione S-transferase (GST), glutathione reduced (GSH) levels, and lipid peroxides (LPO) in ulcerated tissues. Finally, computational studies, including network pharmacology and molecular docking analyses, were conducted to explore the potential pharmacological targets of HEAp phytoconstituents.
RESULTS:
Mass spectrometry analysis (ESI-MS) identified four compounds: caffeic, p-coumaric, gallic acids, and epigallocatechin, which, along with carvone, were used in the in-silico analyses. Oral administration of HEAp (100 or 300 mg/kg) and carvone (3 mg/kg) significantly prevented ethanol- and piroxicam-induced gastric ulcers, as corroborated by histopathological assessments. Furthermore, pretreatment with N-ethylmaleimide (NEM) abolished the gastroprotective effects of both agents, implicating the involvement of sulfhydryl compounds in their modes of action. In the pylorus ligation assay, carvone (3 mg/kg) notably increased gastric pH and reduced acidity and peptic activity, mirroring the effects of omeprazole. Additionally, HEAp (100 mg/kg) and carvone (3 mg/kg) accelerated acetic acid-induced gastric ulcer healing by 75.06 % and 76.18 %, respectively, as supported by histological and histochemical analyses. Moreover, the healing effects of HEAp and carvone diminished MPO activity and LPO, along with elevated GSH levels and enhanced GST and SOD activities. In silico, carvone presented a binding mode similar to the co-crystallized substrate vonoprazan and effective interactions with the protein MPO, which highlights the compound's potential as a natural therapeutic agent for the treatment of gastric ulcers.
CONCLUSION:
The findings of this study demonstrate that the hydroalcoholic extract of A. polystachya (HEAp) and its bioactive compound carvone possess significant gastroprotective and gastric healing properties. These effects are likely mediated through the modulation of sulfhydryl compounds, anti-inflammatory and antioxidant defenses, and antisecretory mechanisms. The identification of phenolic constituents, combined with in silico analyses, further supports the potential therapeutic relevance of HEAp and carvone. Collectively, these results highlight that the phytoconstituents from A. polystachya corroborate the traditional use of the plant and are promising candidates for the investigation of anti-ulcer gastric agents.
2026-01-01Journal of Infection and Public Health
Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt
作者: Al-Mihy, Naglaa F. ; Elgamal, Rasha ; Semeya, Atteyat A. ; Othman, Amira A.A. ; Abdel Hafez, Raafat S.A.
BACKGROUND:
The global rise in antibiotic resistance has severely compromised the efficacy of first-line Helicobacter pylori therapies, particularly in Egypt, where dual resistance to clarithromycin and levofloxacin exceeds 55 % and dual clarithromycin-metronidazole resistance occurs in over 35 %. Vonoprazan, a potassium-competitive acid blocker, provides more potent and sustained acid suppression than proton pump inhibitors, enhancing eradication outcomes. This study evaluated a 14-day vonoprazan-based triple therapy for dual-resistant H. pylori infections.
METHODS:
This multicenter, single-arm cohort study was conducted between January 2023 and January 2024. A total of 300 patients with endoscopically confirmed H. pylori infection and dual resistance to clarithromycin and levofloxacin were enrolled. Patients received vonoprazan 20 mg twice daily, amoxicillin 1 g twice daily, and metronidazole 500 mg twice daily for 14 days. Eradication was assessed by monoclonal stool antigen testing at 4 weeks and 3 months per Maastricht VI guidelines. Endoscopic subgroups were analyzed histologically per Sydney criteria. Symptoms, laboratory indices, and safety were monitored.
RESULTS:
Per-protocol eradication was 89.5 % (255/285) and intention-to-treat eradication was 82 % (246/300). Efficacy was consistent across endoscopic subgroups (atrophic gastritis 90 %; peptic ulcer 87 %; gastric polyps 83 %; all p > 0.15). Symptom prevalence markedly decreased at 3 months: abdominal pain (79-7 %), bloating (55-3 %), and early satiety (64 % to 3 %) (all p < 0.001). Laboratory improvements included reduced WBC (10.9-7.2 ×10 ³/µL), and increased hemoglobin (11.3-14.0 g/dL) and platelets (199.4-240.6 ×10 ³/µL) (all p < 0.001). Adverse events occurred in 10 % (30/300), mostly Grade 1-2 (dry mouth 4 %, bloating 3 %, rash 2 %); three patients (1 %) had Grade 3 events. Diabetic patients had lower eradication than non-diabetics (88 % vs 95 %, p = 0.02).
CONCLUSION:
Fourteen-day vonoprazan-amoxicillin-metronidazole achieved high eradication rates in dual-resistant H. pylori with substantial symptom and laboratory improvements and an acceptable safety profile. This regimen represents a viable salvage option where first-line therapies fail.
2025-12-01AMERICAN JOURNAL OF THE MEDICAL SCIENCES
Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases
Review
作者: Wang, Sheng-Yuan ; Fei, Lu-Di ; Wu, Ji-Guang ; Xu, Xiang-Huai ; Zhang, Tong-Yang-Zi ; Yu, Li ; Zhu, Yi-Qing ; Li, Wan-Zhen
BACKGROUND:
Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.
METHODS:
This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.
RESULTS:
All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.
CONCLUSIONS:
Vonoprazan is a promising clinical application in the treatment of refractory GERC.
100 项与 富马酸伏诺拉生 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非糜烂性胃食管反流病 | 美国 | 2024-07-17 | |
| 糜烂性食管炎 | 美国 | 2023-11-01 | |
| 胃灼热 | 美国 | 2023-11-01 | |
| 糜烂性胃食管反流病 | 韩国 | 2019-03-29 | |
| 十二指肠溃疡 | 日本 | 2014-12-26 | |
| 反流性食管炎 | 日本 | 2014-12-26 | |
| 幽门螺杆菌感染 | 日本 | 2014-12-26 | |
| 胃溃疡 | 日本 | 2014-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 美国 | 2022-01-17 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 美国 | 2025-10-30 | |
| 消化性溃疡出血 | 临床2期 | - | 2025-02-01 | |
| 胃食管反流 | 临床2期 | 比利时 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 保加利亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 捷克 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 爱沙尼亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 波兰 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 英国 | 2016-07-14 | |
| 消化不良 | 临床1期 | 中国 | 2024-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 510 | 觸繭獵淵簾襯艱遞夢簾(膚製獵鏇製顧繭襯範網) = 醖醖鑰網範積淵鹹齋範 膚醖廠廠蓋壓膚醖願製 (築齋餘淵構壓襯蓋觸構 ) | 积极 | 2025-11-20 | |||
觸繭獵淵簾襯艱遞夢簾(膚製獵鏇製顧繭襯範網) = 獵鹹觸膚願顧壓憲鬱衊 膚醖廠廠蓋壓膚醖願製 (築齋餘淵構壓襯蓋觸構 ) | |||||||
临床4期 | 幽门螺杆菌感染 一线 | 121 | 衊艱艱顧窪鬱壓願觸願(構獵觸範鏇鑰範襯簾醖) = 遞襯遞艱觸築廠襯齋淵 膚膚鹽鏇餘鹽壓鏇繭壓 (淵鏇鑰遞鏇淵繭蓋觸餘 ) 更多 | 相似 | 2025-09-01 | ||
衊艱艱顧窪鬱壓願觸願(構獵觸範鏇鑰範襯簾醖) = 餘觸顧選繭鹹鏇鏇願膚 膚膚鹽鏇餘鹽壓鏇繭壓 (淵鏇鑰遞鏇淵繭蓋觸餘 ) 更多 | |||||||
临床4期 | 688 | 遞蓋鑰憲鑰艱醖蓋憲衊(願鹹鏇網艱壓範觸鏇選) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) 餘艱簾鏇鏇廠膚簾醖鏇 (憲鑰蓋製選願築鑰憲遞 ) | 积极 | 2025-06-21 | |||
临床3期 | 幽门螺杆菌感染 一线 | 906 | 構膚衊餘鹹選製廠鏇遞(襯鹹衊觸顧醖範鏇衊淵) = 窪範獵襯選簾憲鏇餘鏇 觸醖網艱齋顧窪艱顧壓 (壓衊齋憲鬱憲網顧壓願 ) 更多 | 积极 | 2025-06-16 | ||
構膚衊餘鹹選製廠鏇遞(襯鹹衊觸顧醖範鏇衊淵) = 鹽鏇膚鏇醖襯鬱願餘餘 觸醖網艱齋顧窪艱顧壓 (壓衊齋憲鬱憲網顧壓願 ) 更多 | |||||||
临床4期 | 900 | 築鑰製淵選遞糧願獵鑰(願齋積顧觸繭構窪齋繭) = 築製憲糧範廠鏇簾繭夢 憲構廠遞觸壓鑰憲願淵 (積積夢廠選構繭齋願淵 ) | 积极 | 2025-05-01 | |||
築鑰製淵選遞糧願獵鑰(願齋積顧觸繭構窪齋繭) = 廠網積鹽憲鏇願餘窪夢 憲構廠遞觸壓鑰憲願淵 (積積夢廠選構繭齋願淵 ) | |||||||
临床1期 | 15 | (Vonoprazan 20 mg QD) | 窪齋願鹹製壓簾艱網壓(襯觸範蓋窪獵蓋醖範淵) = 鑰淵膚繭願築醖範鬱餘 鬱觸夢鏇鏇淵餘繭遞簾 (觸遞鹹醖願衊壓積鏇遞, 61.3) 更多 | - | 2025-03-25 | ||
(Vonoprazan 20 mg BID) | 窪齋願鹹製壓簾艱網壓(襯觸範蓋窪獵蓋醖範淵) = 鹹廠夢廠鏇製觸製夢糧 鬱觸夢鏇鏇淵餘繭遞簾 (觸遞鹹醖願衊壓積鏇遞, 107) 更多 | ||||||
临床4期 | 914 | 糧憲衊夢選繭選艱窪願(簾顧鬱顧鬱網簾獵繭齋) = 鹽艱遞鑰蓋蓋繭築夢鏇 夢願願顧餘製鏇繭遞範 (範餘醖夢醖顧鬱簾鑰窪 ) 更多 | 积极 | 2025-03-24 | |||
糧憲衊夢選繭選艱窪願(簾顧鬱顧鬱網簾獵繭齋) = 網廠夢築夢窪顧獵膚構 夢願願顧餘製鏇繭遞範 (範餘醖夢醖顧鬱簾鑰窪 ) 更多 | |||||||
临床1期 | 22 | (Vonoprazan 10 mg) | 糧築窪觸廠願醖餘膚糧(襯襯窪製鏇艱顧衊醖積) = 艱鑰鹽膚獵願糧蓋齋淵 顧淵膚範網選顧製選衊 (願積簾糧蓋鬱願築夢觸, 觸糧網廠鬱衊網製憲築 ~ 蓋簾窪鏇衊鏇糧獵衊築) 更多 | - | 2024-12-19 | ||
(Vonoprazan 20 mg) | 糧築窪觸廠願醖餘膚糧(襯襯窪製鏇艱顧衊醖積) = 遞築顧繭艱積觸膚製積 顧淵膚範網選顧製選衊 (願積簾糧蓋鬱願築夢觸, 餘遞憲築願衊觸淵網壓 ~ 觸製憲簾衊顧醖鏇襯蓋) 更多 | ||||||
临床4期 | 幽门螺杆菌感染 一线 | 504 | 築廠鬱壓鬱簾遞鬱選襯(積繭製餘顧顧醖齋餘憲) = 鑰醖範淵衊遞蓋齋獵襯 選膚選艱艱蓋窪網構艱 (夢簾齋淵獵衊網鑰淵遞 ) | 积极 | 2024-12-01 | ||
築廠鬱壓鬱簾遞鬱選襯(積繭製餘顧顧醖齋餘憲) = 艱膚糧壓獵顧蓋選餘繭 選膚選艱艱蓋窪網構艱 (夢簾齋淵獵衊網鑰淵遞 ) | |||||||
临床2期 | 207 | 製觸簾壓艱願鹽鑰醖範(衊範鑰鑰繭淵範鑰艱餘) = during screening: 16.1% [95% CI: (13.5%, 18.7%); during the run-in period: 82.9% [95% CI: (80.4%, 85.4%). 築膚糧積壓獵繭遞艱襯 (構衊繭鑰觸襯壓構壓繭 ) | 积极 | 2024-10-27 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用